American College of Clinical Pharmacy
      Search      Cart
         

Clinical Reasoning Series in Pharmacotherapy-- Gut Check Time: An Update in Gastrointestinal Pharmacotherapeutics

Tuesday, October 10, 2017 from 8:30 AM to 5:00 PM MST at Phoenix Convention Center North Building Street Level: Meeting Room 122

Available for 6.00 hours of CPE credit
Activity Number: 0217-0000-17-207-L01-P
Activity Type: An Application-Based Activity

The Clinical Reasoning Series in Pharmacotherapy has been approved by the Board of Pharmacy Specialties (BPS) for the recertification of Board Certified Pharmacotherapy Specialists (BCPSs). The program will focus on contemporary strategies for the optimal treatment of patients with various gastrointestinal diseases and conditions. It will also explore best practices in the management of intra-abdominal issues and diseases. Sessions will detail and apply evidence that helps inform individual patient care and advances pharmacist services. The program will offer 6.0 hours of BCPS recertification credit.

Learning Objectives
1. Determine the best therapeutic option(s) in managing patients with liver disease, pancreatitis, irritable bowel syndrome, inflammatory bowel disease, opioid-induced constipation, or bariatric surgery.
2. Discuss emerging diagnostic and therapeutic options in the management of liver disease, pancreatitis, irritable bowel syndrome, inflammatory bowel disease, opioid-induced constipation, or bariatric surgery.
3. Manage the treatment and processes in transitions of care in patients with liver disease, pancreatitis, irritable bowel syndrome, inflammatory bowel disease, opioid-induced constipation, or bariatric surgery.
4. Design an appropriate monitoring plan for patients with liver disease, pancreatitis, irritable bowel syndrome, inflammatory bowel disease, opioid-induced constipation, or bariatric surgery.
5. Apply clinical and pharmacoeconomic data to individual patient care and formulary decisions regarding drugs used for liver disease, pancreatitis, irritable bowel syndrome, inflammatory bowel disease, opioid-induced constipation, or bariatric surgery
Introduction
8:30 AM to 8:45 AM

Speakers
  • Jeffrey T. Sherer, Pharm.D., MPH, BCPS, BCGPModerator: Jeffrey T. Sherer, Pharm.D., MPH, BCPS, BCGP
    Clinical Associate Professor, University of Houston College of Pharmacy, Houston, Texas

Inflammatory Bowel Disease
8:45 AM to 9:45 AM

Speakers
  • Bryan L. Love, Pharm.D., BCPSFaculty: Bryan L. Love, Pharm.D., BCPS
    Associate Professor, University of South Carolina College of Pharmacy, Columbia, South Carolina
      View Biography


Learning Objectives
1. Interpret emerging diagnostic options in the management of inflammatory bowel disease.
2. Compare therapeutic option(s) in managing patients with inflammatory bowel disease.
3. Analyze medical literature and apply common statistical applications to IBD.
4. Design an appropriate monitoring plan for patients with inflammatory bowel disease.
Updates to the Management of Pain in Chronic Pancreatitis
9:45 AM to 10:45 AM

Speakers
  • Bernadette  Asias-Dinh, Pharm.D., BCACP, BCPS, CDEFaculty: Bernadette Asias-Dinh, Pharm.D., BCACP, BCPS, CDE
    Clinical Assistant Professor, Department of Pharmacy Practice and Translational Research, Texas Medical Center Campus, University of Houston, Houston, Texas
      View Biography


Learning Objectives
1. Compare therapeutic agents that have been studied in the management of pain in chronic pancreatitis.
2. Formulate optimal treatment regimens in the management of pain in chronic pancreatitis.
3. Differentiate between “early invasive” and “step-up” therapy approaches to management of pain in chronic pancreatitis.
Break
10:45 AM to 11:00 AM
Bariatric Surgery
11:00 AM to 12:00 PM

Speakers
  • Amaris  Fuentes, Pharm.D., BCPS, BCCCPFaculty: Amaris Fuentes, Pharm.D., BCPS, BCCCP
    Clinical Specialist in Critical Care, Houston Methodist Hospital, Houston, Texas
      View Biography


Learning Objectives
1. Analyze the role of bariatric surgery in the management of patients with morbid obesity.
2. Examine the complications and medication related changes evident post-bariatric surgery.
3. Evaluate the role of a pharmacist in the care of patients undergoing bariatric surgery procedures.
Lunch
12:00 PM to 1:30 PM
Chronic Liver Disease
1:30 PM to 3:00 PM

Speakers
  • Rima A. Mohammad, Pharm.D., FCCP, BCPSFaculty: Rima A. Mohammad, Pharm.D., FCCP, BCPS
    Clinical Associate Professor of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan
      View Biography


Learning Objectives
1. Outline the current guideline recommendations for the management of complications associated with chronic liver disease (CLD), which include hepatic encephalopathy (HE), ascites, and portal hypertension.
2. Review results from clinical studies to the management of complications associated with CLD.
3. Design evidence-based treatment and prevention regimens in patients with complications associated with CLD.
4. Discuss complications associated with ascites (spontaneous bacterial peritonitis [SBP] and hepatorenal syndrome [HRS]) and portal hypertension (varices and variceal bleeding).
5. Assess and apply information on transitions of care and treatment cost in the management of patients with complications associated with CLD.
Opioid-Induced Constipation
3:00 PM to 3:30 PM

Speakers
  • Faculty: Rima A. Mohammad, Pharm.D., FCCP, BCPS
    Clinical Associate Professor of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan
      View Biography


Learning Objectives
1. Evaluate clinical studies and guidelines on the management of opioid-induced constipation (OIC).
2. Design evidence-based treatment and prevention regimen in patients with OIC.
3. Assess and apply information on transitions of care and treatment cost in the management of patients with OIC.
Break
3:30 PM to 3:45 PM
Irritable Bowel Syndrome
3:45 PM to 4:45 PM

Speakers
  • Faculty: Bryan L. Love, Pharm.D., BCPS
    Associate Professor, University of South Carolina College of Pharmacy, Columbia, South Carolina
      View Biography


Learning Objectives
1. Assess symptoms of IBS including the most common clinical presentations.
2. Recognize warning signs that require further evaluation prior to initiating IBS therapy.
3. Compare the safety and efficacy of eluxadoline, lubiprostone, and linaclotide for the treatment of IBS.
4. Develop a pharmacotherapy regimen for a given patient case.
Closing Remarks
4:45 PM to 5:00 PM

Speakers
  • Moderator: Jeffrey T. Sherer, Pharm.D., MPH, BCPS, BCGP
    Clinical Associate Professor, University of Houston College of Pharmacy, Houston, Texas